Clinical Chemistry April 2011
Michael Kleerekoper, Moderator1, mkleerekoper at med.wayne.edu
Rosemary L. Schleicher2, John Eisman3,4,5, Roger Bouillon6, Ravinder J. Singh7 and Michael F. Holick, Experts8
1 Wayne State University, St. John River District Hospital, East China, MI;
2 Nutritional Biomarkers Laboratory, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA;
3 University of New South Wales, Sydney, Australia;
4 St. Vincent's Hospital, Sydney, Australia;
5 Osteoporosis and Bone Biology Research Program, Garvan Institute of Medical Research, Sydney, Australia;
6 Experimental Medicine and Endocrinology Section, K.U.Leuven, Leuven, Belgium;
7 Endocrine Laboratory, Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;
8 General Clinical Research Center, Boston University School of Medicine, Boston, MA.
Questions asked - CLICK HERE for answers
What should we measure: 25-OHD3, 25-OHD2, both, or 1,25-OHD?
Is there a preferred assay for the measurement of vitamin D metabolites?
How stable are 25-OHD and 1,25-OHD during transport?
What are the clinical indications for measurement of 25-OHD in disorders of bone and mineral metabolism, or other situations?
What reference ranges should be used for reporting 25-OHD results, and should they be stratified by sex, ethnicity, age, and season?
How important are sunscreens and sun hats in regulating synthesis of vitamin D?
How valid are the epidemiologic data relating vitamin D to diseases outside the skeleton?
What are the mechanisms controlling 1,25-OHD production outside the kidney?
Is there a role for determining polymorphisms in the vitamin D receptor (VDR)?
In an era of shrinking resources in healthcare and given the existing clinical and population studies, do you support the measurement of vitamin D in general practice in subjects with no clinical signs or suspicion of bone disease?